Single Cell Analysis Market: Global Overview and Forecast (2023-2029)

Single Cell Analysis Market size was valued at USD 3.34 Bn. in 2022 and the total Single Cell Analysis revenue is expected to grow at 15.3% from 2023 to 2029, reaching nearly USD 9.05 Bn.
Single Cell Analysis Market Overview:
Single-cell analysis (SCA) is a vital technique that is widely utilized in cell biology and biomedicine. SCA is an excellent tool for acquiring a thorough understanding of biological heterogeneity and influencing therapy decisions. Breast cancer, lung cancer, brain cancer, colon cancer, bladder cancer, acute myeloid leukemia, and melanoma have all been treated with it. Immunology, microbiology, neurobiology, prenatal diagnostics, embryogenesis, and plant biology all use SCA. Single-cell sequencing is a great technique for studying the genomes of bacteria that cannot be grown.

Microbial ecology that cannot be grown is referred to as biological dark matter, and it accounts for around 99% of microbe species. Plaque bacteria from human teeth was the first uncultured microorganism to be sequenced using single-cell sequencing. In summary, single-cell applications are developing every day, and they will eventually increase understanding of many biological processes.

SCA is in high demand in omics research activities such as genomics, proteomics, transcriptomics, and metabolomics. Single-cell omics research aids in the processing of large data sets and the understanding of genetic underpinnings. It is the key to conquering human health advancement through illness detection and medication research. High throughput assays, effective cell sorting and tagging, sequencing, microfluidics, single-cell amplification, and enhanced software tools have all emerged from technological advancement. The availability of these items and their broad application areas are increasing the market's revenue organically.

The increasing need for analytical tools for revolutionary research, as well as subsequent financing, has resulted in the market launch of high-throughput equipment. Multiple advancements have led to this equipment incorporating features like automation, high sensitivity, and precision, all of which aid in the analysis of a few samples. Deepcell Inc., a U.S.-based startup, for example, secured USD 73 million in investment in March 2022 to develop and commercialize its AI-powered single cell analysis platform. As a result, important companies are considerably spending on creating solutions, resulting in a profitable income generating potential during the forecast period.

However, the market growth would face limitations due to the high cost of these instruments and consumables. The ongoing maintenance expenditures and other expenses associated with these devices would impose restraints on various clinical and research applications with limited budgets.To know about the Research Methodology :- Request Free Sample Report
Single Cell Analysis Market Dynamics:
Rising prevalence of Cancer patients across the globe

Cancer is one of the leading causes of mortality globally. The illness has grown significantly in recent years and is expected to increase substantially throughout the forecast period. Cancer is a primary cause of mortality globally, accounting for approximately 10 million deaths in 2020, or roughly one in every six deaths, according to the World Health Organization (WHO). Every year, around 400 000 youngsters are diagnosed with cancer. The most frequent cancers differ by country. Thus, the rising global prevalence of cancer increases the rate of diagnosis and the need for better diagnostics, driving the market.

However, according to the International Agency for Research on Cancer (IARC), the global cancer burden is expected to rise to 27.5 million new cancer cases and 16.3 million deaths by 2040. Circulating tumor cells are increasingly attracting therapeutic attention since it may allow for the monitoring of disease development and therapy adjustments. Single-cell sequencing has identified diagnostic and prognostic biomarkers.

Cancer genomics is one of the most important applications of single-cell analysis. GLOBOCAN predicts that the number of cancer cases would climb to almost 30 million by 2040, up from 19.3 million cases and 10 million cancer deaths in 2020. The increasing frequency of this disease has necessitated substantial investigation for diagnosis and therapy; single-cell analysis is a key component of this research. Individual cell analysis allows for accurate illness diagnosis and therapy efficacy monitoring. Single-cell analysis assists in the identification of helper T-cells, the assessment of DNA content, and the monitoring of tumor cell growth in breast cancer and other malignancies.

Growing potential for single-cell sequencing

Single-cell sequencing is considered to be an effective technique for identifying illness-specific biomarkers that may be used to diagnose and track the development and progression of a disease, as well as the patient's response to therapy. Companies are working on producing equipment and reagents suited for single-cell sequencers since SCS technology delivers substantial insights into genetic alterations. Given this segment's strong growth potential, numerous advanced SCS equipment is expected to be developed and released in the market during the forecast period.

High cost of single-cell analysis products

The price of single-cell biology research is expensive due to the requirement to maintain high-quality standards (the use of high-grade, expensive materials) and comply with regulatory bodies' guidelines. However, due to financial restrictions, such expensive devices are difficult to afford in research and academic institutions. Additionally, the cost of maintenance and a variety of additional indirect charges raise the total cost of ownership of these devices. This is a key constraint to the widespread use of flow cytometers and microfluidic devices in clinical and research settings.
Single Cell Analysis Market Segment Analysis:
By Application, the Research Application held the largest market share and dominated the market in 2022. This segment is further expected to grow at a CAGR of 14.2% and dominated the market at the end of the forecast period. The increasing prevalence of cancer, the growing demand for stem cell research, initiatives for early identification of chronic illnesses, and increased awareness of commercially accessible cancer diagnostics and precision medicine all contribute to the largest market share.

Cancer and immunology are two areas of research that are gaining popularity among researchers. Canopy Biosciences, a Bruker Company, provide ChipCytometry test kits in December 2022. The Canopy assay kits can be used to quantitatively scan dozens of specific protein biomarkers on a single tissue segment at a single-cell spatial resolution, streamlining the user experience with ChipCytometry and allowing for a faster route to important biological advancements.According to clinicaltrials.gov, there were about 23,358 active, ongoing clinical studies in cancer as of March 2022. This reflects the high rate of cancer research being conducted globally, and because the cellular, metabolic, and genetic study and evaluation of tumor cells plays an important role in the understanding of various cancers, leading to the development of effective diagnostic tests, therapeutic applications, and potential treatments for cancer, the use of single-cell analysis in research applications is expected to grow significantly.

However, immunological tests contribute to the early diagnosis of therapeutic problems, such as various cancer and hematology-based indications, enhancing treatment efficiency. According to research published in the Journal of Immunology Research in 2020, single-cell RNA sequencing and analysis aid in the study of the immune response to diverse illnesses, which can lead to the creation of effective vaccines against causative organisms. Additionally, the invasion of single-cell metabolic activities is increasing the acceptance of its analytical techniques, driving the growth of the research application segment.

By End-Users, the academic and research laboratories segment dominated the market with the highest market share in 2022 and is expected to grow at a CAGR of 13.8% during the forecast period. The dominance of the segment is attributed to the increasing application of single-cell analysis techniques in research. A large number of active scientific research at various institutions that use SCA methodologies has pushed for its implementation in 2022. Another significant factor driving the industry is the development of spatial genomics, which speeds single-cell analysis in research operations.

However, the industry is being driven by the development of new tools to address research limitations. For example, in June 2022, researchers at Stony Brook University in New York produced a new biomedical research tool, single-cell cyclic multiplex in situ tagging (CycMIST) technology. This method allows scientists to evaluate functioning proteins in a single cell, which helps in the diagnostic and research industries.Technological advancements, such as the use of microfluidics in the production of cell and gene treatments, have enhanced biotechnology and pharmaceutical organizations' adoption of SCA. Additionally, increased multi-omics penetration in medication development research would increase the market during the forecast period.

A significant number of organizations have invested in genomics in order to have access to diverse genome databases. For example, Life bit, a big data organization located in the United Kingdom, established a partnership with Boehringer Ingelheim in March 2022. The collaboration would utilize Lifebit's Cloud OS, the first federated genomics platform, to construct a data analytics infrastructure for Boehringer. This infrastructure would collect illness insights from biobanks in order to create treatments. In 2022, Boehringer will also be coupled with Lifebit's REAL platform to speed up the diagnosis and tracking of disease outbreaks.
Single Cell Analysis Market Regional Insights:
North American market dominated the Single Cell Analysis market with the largest market share in 2022 and is expected to maintain its dominance at the end of the forecast period. The large share of the North American market is due to factors such as the existence of big rivals, increased partnerships among key companies, technological developments, and the increasing pharmaceutical and biotechnology industries.

Various government initiatives have been implemented in recent years to support the growth of the region's single-cell analysis industry. Biognosys, for example, announced an extended range of proteomics technologies in March 2022 to give pharmaceutical and diagnostics companies with comprehensive biological insights across the whole R&D pipeline, from early-stage discovery to clinical settings. Similarly, in January 2022, Amgen announced a collaboration with Generate Biomedicines to find and develop protein therapies for five targets spanning different therapeutic areas and modalities, with an initial investment of USD 1.9 billion or more.

In addition, the region's increasing prevalence of chronic disorders such as cancer is driving the market growth. According to the Globocan 2020 report, an estimated 2,281,658 cases of new cancer were diagnosed in the United States in 2020, with nearly 612,390 deaths. In the United States in 2020, the most frequent cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809).

Besides that, the presence of significant competitors in the area, as well as novel product launches, are expected to drive the single-cell analysis market during the forecast period. For example, the US Food and Drug Administration authorized Abecma (idecabtagene vicleucel) in March 2022 for the treatment of adult patients with multiple myeloma who have not responded to, or whose cancer has relapsed after, at least four prior lines of therapy. Abecma is the first FDA-approved cell-based gene therapy for the treatment of multiple myeloma. As a result, the single-cell analysis market in North America is expected to increase significantly throughout the forecast period.

The Asia-Pacific regional market is expected to grow at a CAGR of 13.2% during the forecast period. The increasing focus on customized treatment increased R&D in the pharmaceutical and biotechnology companies for complicated disorders, and the growth of stem cell research drive the market growth during the forecast period. The regional market is dominated by pharmaceutical and biotechnology organizations. Single-cell analysis is used in the development and manufacturing of all biopharmaceutical products. Growth in the Asia Pacific pharmaceutical and biotechnology industry is a direct driver of associated markets such as single-cell analysis.

Pharmaceutical and biotechnology organizations use single-cell analysis solutions to meet clinical research aims and objectives. Biopharmaceutical businesses are primarily concerned with the development of targeted treatments, particularly for the treatment of cancer, complicated illnesses, and uncommon genetic abnormalities. As organizations focus on creating targeted medicines, the necessity for single-cell analysis technologies to determine the genetic profile of patients enrolled in clinical trials has grown critical. Similarly, drug manufacturers are using single-cell analysis equipment such as NGS technologies for biomarker research, which is a segment with a significant CAGR during the forecast period.
Single Cell Analysis Market Scope: Inquiry Before Buying



Single Cell Analysis Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 3.34 Bn.


Forecast Period 2023 to 2029 CAGR:
15.3 %
Market Size in 2029:
US $ 9.05 Bn.


 Segments Covered:
by Product
1. Consumables
1.1. Reagents
1.2. Assay Kits
2. Instruments
2.1. Flow Cytometers
2.2. NGS Systems
2.3. PCR Instruments
2.4. Spectrophotometers
2.5. Microscopes
2.6. Cell Counters
2.7. HCS Systems
2.8. Microarrays
2.9. Other Instruments
2.10. Single Cell Analysis, by Cell Type
2.11. Human Cells
2.12. Animal Cells
2.13. Microbial Cells


by Technique
1. Flow Cytometry
2. Next-generation Sequencing
3. Polymerase Chain Reaction
4. Microscopy
5. Mass Spectrometry
6. Other Techniques


by Application
1. Research Applications
1.1. Cancer
1.2. Immunology
1.3. Neurology
1.4. Stem Cell
1.5. Other Research Applications
1.6. Medical Applications
1.7. Noninvasive Prenatal Diagnosis
1.8. in Vitro Fertilization
1.9. Circulating Tumor Cell Detection


by End-Users
1. Academic & Research Laboratories
2. Biotechnology & Pharmaceutical Companies
3. Hospitals & Diagnostic Laboratories
4. Cell Banks & IVF Centers



Single Cell Analysis Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Single Cell Analysis Market, Key Players are:
1. Becton, Dickinson and Company (US)
2. Danaher Corporation(US)
3. NanoCellect Biomedical(US)
4. Thermo Fisher Scientific, Inc.(US)
5. 10x Genomics(US)
6. Fluxion Biosciences(US)
7. Promega Corporation(US)
8. Luminex Corporation(US)
9. Illumina, Inc.(US)
10. Bio-Rad Laboratories(US)
11. Cytek Biosciences(US)
12. Corning Incorporated(US)
13. Fluidigm Corporation(US)
14. Agilent Technologies, Inc.(US)
15. Rarecyte Inc.(US)
16. Merck KGAA (Germany)
17. Sartorius AG(Germany)
18. QIAGEN N.V.(Germany)
19. Tecan Group Ltd.(Switzerland)
20. Takara Bio (Japan)
21. On-chip Biotechnologies Co., Ltd.( Japan)
22. Menarini Silicon Biosystems, Inc.(France)
23. bioMérieux SA(France)
24. Oxford Nanopore Technologies(UK)
25. Apogee Flow Systems Ltd.(UK)

FAQs:

1. Which is the potential market for the Single Cell Analysis in terms of the region?
Ans. North America is the potential market for Single Cell Analysis in terms of the region.

2. What are the opportunities for new market entrants?
Ans. The key opportunity in the market is the Growing potential for single-cell sequencing.

3. What is expected to drive the growth of the Single Cell Analysis market in the forecast period?
Ans. A major driver in the Single Cell Analysis market is the Rising prevalence of Cancer patients across the globe.

4. What is the projected market size & growth rate of the Single Cell Analysis Market?
Ans. The Single Cell Analysis Market size was valued at USD 3.34 Bn. in 2022 and the total Single Cell Analysis revenue is expected to grow by 15.3% from 2023 to 2029, reaching nearly USD 9.05 Bn.

5. What segments are covered in the Single Cell Analysis Market report?
Ans. The segments covered are Product, Technique, Application, End users, and Region.